Why JNJ Matters Now
Johnson & Johnson is trading near its historical overvaluation band. Current yield 2.1% vs historical max 4.9% (42% of maximum). 14 consecutive years without a dividend cut. Reasonable payout ratio of 60%.
Weiss Valuation: Where Does JNJ Stand Today?
At 2.06%, JNJ's current yield is near the bottom of its 10-year historical range (2.78%–4.91%). By the Weiss method this indicates that the market is pricing the stock for optimism — investors are paying a premium relative to the income the stock generates. The historical median yield is 3.27%, suggesting the stock is trading well above fair value.
The undervalued price threshold — the level at which JNJ historically becomes an attractive buy — currently sits at $153.90. The overvalued threshold, above which the stock is historically expensive, is $194.08. The current price of $254.66 places the stock above the overvalued band — a signal to review position sizing.
Dividend Quality Assessment
Johnson & Johnson scores 47/100 on DividendVisual's quality scale — a Below Average rating. Investors should carefully review dividend sustainability before acting on the Weiss signal. Key metrics: a 60% payout ratio, the dividend consumes 103% of free cash flow, growing at 5.2% annually over the past 5 years.
Johnson & Johnson has raised its dividend for 64 consecutive years — qualifying it as a Dividend King, the most elite category of income stocks.
The current payout ratio is 60% — a moderate level. The dividend is well-covered but investors should monitor any trend toward higher payout.
Peer Context: Is JNJ the Best Setup?
JNJ is not the only candidate in Healthcare. BDX offers a higher current yield, while SYK screens higher on quality. That makes peer comparison important before treating JNJ's Weiss signal as the best available setup.
10-Year Yield History
Over the past decade, Johnson & Johnson's dividend yield has ranged from a low of 2.78% (when the stock was most expensive relative to its dividend) to a high of 4.91% (when it was most attractively priced). The historical median yield — a reasonable proxy for fair value — is 3.27%.
Investors who consistently bought JNJ near its historical yield maximum and held for 3–5 years have, historically, earned both above-average income and above-average capital appreciation as the yield mean-reverted toward the median. This is the core logic of yield-based valuation: price and yield are inversely related, so buying high yield means buying low price.
Income Projection: What JNJ Could Generate
A $10,000 investment at the current price and yield would generate approximately $206 in year-one income. With dividends reinvested and a 5.2% annual growth rate maintained, that same investment would produce roughly $450 per year in income by year 10 — a yield on cost of 4.5%.
These projections assume no share price appreciation — only the compounding effect of reinvested dividends at a constant price. In practice, share price changes will affect the total return. The projection is intended to illustrate the power of dividend reinvestment over time, not to predict a specific outcome.
Key Risks to Consider
Investors should be aware of the following factors: FCF payout coverage of 103%, meaning the dividend consumes the majority of free cash flow; an overall quality score below 50, warranting additional due diligence on dividend sustainability. These do not necessarily signal an imminent dividend cut, but they reduce the margin of safety relative to higher-scoring peers.
For healthcare dividend stocks, patent cycles, reimbursement pressure, product pipelines, and litigation can matter as much as current payout ratios. A safe-looking dividend still needs durable earnings power behind it.
Beyond company-specific factors, all dividend stocks carry interest rate risk: when rates rise, income investors have alternatives, and dividend stock valuations tend to compress. Johnson & Johnson's position in the Healthcare sectorshould be evaluated in the context of your portfolio's overall rate sensitivity.
What to Watch Next
- Yield moving toward 4.91% would strengthen the undervaluation signal; yield falling toward 3.27% would indicate mean reversion.
- Payout ratio staying below 60% would support dividend flexibility.
- Free-cash-flow payout near 103% should be monitored for deterioration.
- Dividend growth above 5.2% would confirm the income-compounding case; a slowdown would reduce the appeal.
- Any break in the 64-year dividend growth streak would materially change the thesis.
Bottom Line
At current prices, Johnson & Johnson is trading at historically elevated valuations relative to its dividend yield. Income investors may find better entry points elsewhere in the dividend universe. Existing holders have no urgent reason to sell — the dividend remains intact — but initiating a new position here means accepting below-median long-term income returns relative to cost.